#Canada #Toronto #Neuroscience #Transpharmation #OrganoTherapeutics

Transpharmation Ltd. Enhances Research Potential with the Acquisition of OrganoTherapeutics SARL

Toronto, October 28, 2026 - In a significant move within the field of neuroscience research, Transpharmation Ltd., a global leader in preclinical contract research, has announced its acquisition of OrganoTherapeutics SARL. This strategic acquisition is expected to bolster Transpharmation’s capabilities in the realms of neurodegenerative diseases, pain management, and metabolic conditions.

The integration of OrganoTherapeutics, which specializes in patient-derived organoid technologies, aims to revolutionize drug discovery and therapy development for disorders such as Alzheimer’s disease and Parkinson’s disease. Dr. Mark Duxon, CEO of Transpharmation, emphasized the importance of this acquisition, stating, “For the past 25 years, we have built a reputation in the field of in vivo translational pharmacology. With OrganoTherapeutics joining our team, we are taking a crucial step toward realizing our ambition of developing translational contract research services that integrate human tissues and systems.”

A New Era in Neuroscience Research

The landscape of neurological research has undergone a transformative shift, largely propelled by advances in genomics, biomarkers, and patient-derived cellular models. With these advancements, researchers are now equipped to tackle the complexities of neurodegenerative diseases more effectively and efficiently. The partnership between Transpharmation and OrganoTherapeutics aims not only to enhance drug discovery processes but also to provide greater predictive capabilities concerning the efficacy and actions of therapeutics before they advance to clinical trials.

Dr. Jens Schwamborn, co-founder of OrganoTherapeutics, echoed the sentiment of progress, stating, “Joining Transpharmation is a logical next step for OrganoTherapeutics. Over the years, we have developed sophisticated human brain organoid and ‘assembloid’ models derived from induced pluripotent stem cells (iPSCs) for various neurodegenerative diseases, enabling us to conduct critical studies alongside our pharmaceutical and biotechnology partners.”

Combining Forces for Better Outcomes

By uniting their respective strengths, Transpharmation and OrganoTherapeutics are poised to significantly advance the field of translational neuroscience. The merged expertise will empower biopharmaceutical companies to explore disease biology, validate therapeutic targets, and assess novel treatments more effectively, employing advanced and human-relevant models.

Transpharmation’s commitment to eliminating animal testing in certain aspects of preclinical research aligns with emerging ethical concerns and industry trends. This acquisition places the company at the forefront of utilizing 3D patient-derived organoids, particularly within the field of neurology, which is anticipated to enhance clients' confidence in their therapeutic candidates.

As scientists gain access to human-relevant predictive systems and a wealth of biological insights, the pace of discovery in neurodegenerative disorders is expected to accelerate. The comprehensive team of organoid and neurodegenerative disease experts will provide a suite of resources tailored to empower medical researchers in their quests for breakthrough therapies.

Understanding Human-Derived Organoids

Human-derived organoids are miniature models of human brain tissue, cultivated from stem cells provided by healthy volunteers or patients. These organoids replicate many critical cell types essential for studying brain diseases effectively — such as Parkinson's disease — allowing researchers to test promising new treatments before moving to clinical trials.

OrganoTherapeutics, headquartered in Luxembourg, is pioneering advanced organoid and assembloid models tailored to individual patients suffering from neurodegenerative diseases, applying these models in collaborative studies with pharmaceutical and biotechnology entities. Their innovative approaches stand to transform how researchers understand and develop therapies for severe neurological conditions.

Looking Ahead

The integration of OrganoTherapeutics into Transpharmation’s portfolio is expected to create a more streamlined research process that minimizes costly setbacks in drug development phases and expedites the availability of effective therapies to patients. With a dedication to transforming lives through groundbreaking research, Transpharmation is set to remain a key contributor to the advancement of neuropharmacology and beyond.